retatrutide type 2 diabetes phase 2 trial ESC 2024: improves lipid and cardiovascular risk profile in II Eli Lilly's Retatrutide Advances Toward

Cookies to improve the page On this page we regularly test new motifs

However, alcohol complicates GLP-1 therapy in other ways

Rethinking Risk Thresholds in Diabetes Care May 12, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,120 views A patient loses 30 pounds, lowers their A1C, and improves their blood pressure within months of starting a GLP-1 medication

The benzyl alcohol preservative in bacteriostatic water provides antimicrobial protection throughout the 30-day usage window

Avoid: All GLP-1 patches until Phase 3 clinical trials demonstrate their efficacy, which is not expected until 2030 or later, when microneedle technology may enable effective transdermal delivery of medications like semaglutide

Yet most primary care physicians (PCPs) are skeptical of telehealth platforms prescribing GLP-1s for weight loss